Allogene Therapeutics, Inc.

NASDAQ:ALLO

2.88 (USD) • At close September 18, 2024
Bedrijfsnaam Allogene Therapeutics, Inc.
Symbool ALLO
Munteenheid USD
Prijs 2.88
Beurswaarde 602,242,560
Dividendpercentage 0%
52-weken bereik 2.01 - 5.78
Industrie Biotechnology
Sector Healthcare
CEO Dr. David D. Chang M.D., Ph.D.
Website https://www.allogene.com

An error occurred while fetching data.

Over Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive

Vergelijkbare Aandelen

Instil Bio, Inc. logo

Instil Bio, Inc.

TIL

66.1 USD

SomaLogic, Inc. logo

SomaLogic, Inc.

SLGC

2.1 USD

Celularity Inc. logo

Celularity Inc.

CELU

2.56 USD

Innoviva, Inc. logo

Innoviva, Inc.

INVA

19.54 USD

Adaptive Biotechnologies Corporation logo

Adaptive Biotechnologies Corporation

ADPT

4.61 USD

Silk Road Medical, Inc logo

Silk Road Medical, Inc

SILK

27.49 USD

Cassava Sciences, Inc. logo

Cassava Sciences, Inc.

SAVA

30.32 USD

NGM Biopharmaceuticals, Inc. logo

NGM Biopharmaceuticals, Inc.

NGM

1.54 USD

Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc.

AGIO

45.54 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)